Biologic response modifiers: Indications, implications, and insights
The field of biologic immune modulators is currently mushrooming at a dizzying pace. Although most of these biologics are tested and approved for one or a few indications, their unanticipated side effects and off-label use have contributed significantly to our understanding of basic immune mechanism...
Saved in:
| Published in | Journal of allergy and clinical immunology Vol. 139; no. 5; pp. 1445 - 1456 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.05.2017
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The field of biologic immune modulators is currently mushrooming at a dizzying pace. Although most of these biologics are tested and approved for one or a few indications, their unanticipated side effects and off-label use have contributed significantly to our understanding of basic immune mechanisms, the involvement of cytokines in several apparently nonimmunologic diseases, and the importance of compartmentalized immune responses. In this review we attempt to give a bird's-eye view of the major biologics and to highlight insights and implications derived from their secondary effects and adverse reactions. |
|---|---|
| AbstractList | The field of biologic immune modulators is currently mushrooming at a dizzying pace. Although most of these biologics are tested and approved for one or a few indications, their unanticipated side effects and off-label use have contributed significantly to our understanding of basic immune mechanisms, the involvement of cytokines in several apparently nonimmunologic diseases, and the importance of compartmentalized immune responses. In this review we attempt to give a bird's-eye view of the major biologics and to highlight insights and implications derived from their secondary effects and adverse reactions. Abstract The field of biologic immune-modulators is currently mushrooming at a dizzying pace. While most of these biologics are tested and approved for one or a few indications, their un-anticipated side effects and their off-label use have contributed significantly to our understanding of basic immune mechanisms, of the involvement of cytokines in several apparently non-immunologic diseases, and of the importance of compartmentalized immune responses. In this review, we attempt to give a bird's-eye view of the major biologics and to highlight insights and implications derived from their secondary effects and adverse reactions. |
| Author | Ballas, Zuhair K. Davis, Benjamin P. |
| Author_xml | – sequence: 1 givenname: Benjamin P. surname: Davis fullname: Davis, Benjamin P. email: ben-davis@uiowa.edu organization: Department of Internal Medicine, Division of Immunology, University of Iowa Hospitals and Clinics, Iowa City, Iowa – sequence: 2 givenname: Zuhair K. surname: Ballas fullname: Ballas, Zuhair K. organization: Department of Internal Medicine, Division of Immunology, University of Iowa and the Iowa City Veterans Administration, Iowa City, Iowa |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28263774$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkVFr1TAUx4NM3N30C_ggBV9td5I0bTpEcFPnYLAH9TmkyelM7U3ukl5h336pd2MwcHsKJ_x_53B-54Ds-eCRkLcUKgq0ORqrURtXMaBtBawCyl-QFYWuLRvJxB5ZAXS0bNq62ycHKY2Qay67V2SfSdbwtq1X5MuJC1O4cqaImDbBJyzWwbrBYUzHxbm3zujZ5f8PhVtvpodKe1s4n9zV7zm9Ji8HPSV8c_cekl_fvv48_V5eXJ6dn36-KI3g9Vz2rGZ06LBmxuoegNmGG2TYi77pjZVi6Cgd0HBpuWBU6wZ4LURnBHLbmJ4fkve7vpsYrreYZjWGbfR5pKKyEwJASpFT7-5S236NVm2iW-t4o-6XzgG5C5gYUoo4KOPmf3vNUbtJUVCLXzWqxa9a_CpgKvvNKHuE3nd_Evq4gzC7-ZvNqmQceoPWRTSzssE9jX96hJvJ-XyJ6Q_eYHpQoFIG1I_l6svRacuBc7Hse_z_Bs9NvwUo9rue |
| CitedBy_id | crossref_primary_10_1016_j_annder_2018_07_009 crossref_primary_10_1016_j_jaci_2017_11_024 crossref_primary_10_1016_j_jaci_2018_02_042 crossref_primary_10_1093_ajhp_zxab257 crossref_primary_10_1024_1661_8157_a003003 crossref_primary_10_1080_14740338_2020_1767585 crossref_primary_10_1007_s11033_021_06752_9 crossref_primary_10_1016_j_chest_2020_05_598 crossref_primary_10_1016_j_nano_2019_102017 crossref_primary_10_3389_fimmu_2019_01013 crossref_primary_10_1016_j_bjp_2019_01_010 crossref_primary_10_3238_arztebl_2019_0703 crossref_primary_10_3389_fphar_2024_1452300 crossref_primary_10_1007_s12016_021_08879_w crossref_primary_10_1159_000502687 crossref_primary_10_1097_IOP_0000000000002573 crossref_primary_10_1016_j_pcl_2018_04_008 crossref_primary_10_1097_CCM_0000000000004020 crossref_primary_10_1542_pir_2017_0308 crossref_primary_10_1021_acsabm_9b00200 crossref_primary_10_1542_peds_2021_056021 |
| Cites_doi | 10.1093/qjmed/hcu094 10.1016/j.smim.2014.09.008 10.1038/nrd3800 10.1200/JCO.2012.41.6750 10.1016/j.jaip.2014.12.006 10.21037/sci.2016.09.13 10.1038/nri3823 10.1016/j.jaci.2007.10.028 10.1016/j.clml.2012.11.011 10.1111/bjd.13348 10.1111/ajt.12460 10.1111/bjd.12214 10.1016/S0009-9236(99)90083-8 10.1056/NEJMoa1609214 10.1111/cas.12617 10.1016/S0140-6736(12)60988-X 10.1016/j.jdermsci.2011.05.005 10.1016/S0140-6736(08)60726-6 10.1111/apt.13736 10.4049/jimmunol.142.8.2660 10.3748/wjg.v17.i34.3881 10.1212/WNL.0b013e3182478d4b 10.4161/mabs.2.3.11782 10.1007/s11864-016-0434-0 10.1007/978-3-642-00663-0_16 10.1016/j.jaci.2015.11.004 10.1016/j.jaci.2005.03.028 10.1002/1097-0142(19900401)65:7<1521::AID-CNCR2820650712>3.0.CO;2-Y 10.1038/nri2691 10.1016/j.semarthrit.2015.10.001 10.1016/j.jaci.2007.11.016 10.1164/rccm.200701-085OC 10.1097/QCO.0b013e32832dda55 10.7326/0003-4819-144-12-200606200-00003 10.1189/jlb.5RI0516-237RR 10.1086/505430 10.1111/j.1600-6143.2010.03016.x 10.2217/imt-2016-0020 10.1002/art.30463 10.1111/imr.12272 10.1056/NEJMoa1104621 10.4049/jimmunol.140.6.1883 10.1016/S1474-4422(14)70028-6 10.1056/NEJMoa0810652 10.1586/17474086.2014.953926 10.3899/jrheum.120906 10.1056/NEJMoa1505066 10.1097/BOR.0b013e32835b1366 10.1016/j.jaci.2015.10.010 10.1016/j.jhep.2016.02.004 10.1136/annrheumdis-2013-203843 10.1016/j.jaci.2015.10.023 10.1586/1744666X.2015.1077702 10.1016/j.gtc.2014.05.004 10.1111/j.1469-0691.2006.01546.x 10.1016/j.jaci.2014.12.1947 10.1056/NEJMoa035075 10.1056/NEJMoa074943 10.1155/2014/179180 10.1111/j.1365-2036.2012.05189.x 10.1080/15476910801897433 10.1016/j.jaad.2015.05.013 10.1097/ACI.0b013e3283402b41 10.1097/MD.0b013e3181441a68 10.1016/j.trsl.2014.10.010 10.1093/rheumatology/keq343 10.1016/j.arbres.2014.02.002 10.1136/annrheumdis-2013-205067 10.1200/JCO.1997.15.10.3266 10.1056/NEJMoa063842 10.1016/j.semarthrit.2010.11.002 10.1016/j.alit.2016.04.011 10.1056/NEJMoa0810787 10.1016/j.jaip.2014.06.003 10.1111/bjh.12347 10.1111/j.1600-6143.2009.03005.x 10.1177/1759720X15586782 10.1056/NEJMoa1003466 10.1002/mus.20924 10.1016/S0140-6736(15)61134-5 10.1136/gut.2008.163683 10.1136/gutjnl-2011-301668 10.3747/co.2007.118 10.1158/1078-0432.CCR-11-1595 10.1056/NEJMoa011110 10.1038/nri.2016.93 10.1056/NEJMe058122 10.1056/NEJMoa1506027 10.1016/j.imbio.2013.04.021 10.1016/j.amjmed.2010.11.028 10.1016/j.jbspin.2011.10.001 10.1002/art.22070 10.1586/eci.09.31 10.1586/17512433.2016.1133289 10.1056/NEJMc080834 10.1016/S0140-6736(08)60725-4 10.1093/cid/cit376 10.1001/jamadermatol.2015.4992 10.1159/000334805 10.1155/2014/386148 10.1182/blood.V94.7.2217.419k02_2217_2224 10.1016/j.autrev.2009.10.003 10.1126/science.1128346 10.1016/j.jaci.2015.06.035 10.1016/j.semarthrit.2009.09.001 10.1007/s10620-011-1611-4 10.1038/nri3862 10.1016/j.jaci.2016.10.005 10.1185/03007995.2015.1011778 10.1056/NEJMoa1403290 10.1111/j.1346-8138.2011.01347.x 10.3109/08830185.2012.690794 10.1136/annrheumdis-2011-200316 10.1200/JCO.1998.16.8.2825 10.1016/S2213-2600(15)00042-9 |
| ContentType | Journal Article |
| Copyright | 2017 Published by Elsevier Inc. Copyright Elsevier Science Ltd. May 1, 2017 |
| Copyright_xml | – notice: 2017 – notice: Published by Elsevier Inc. – notice: Copyright Elsevier Science Ltd. May 1, 2017 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7SS 7T5 H94 K9. NAPCQ |
| DOI | 10.1016/j.jaci.2017.02.013 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Entomology Abstracts (Full archive) Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Entomology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts |
| DatabaseTitleList | MEDLINE Entomology Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-6825 |
| EndPage | 1456 |
| ExternalDocumentID | 28263774 10_1016_j_jaci_2017_02_013 S0091674917303354 1_s2_0_S0091674917303354 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA086862 |
| GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 354 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8F7 8FE 8FH 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN ADXHL AEBSH AEIPS AEKER AENEX AEUPX AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BPHCQ BVXVI C45 CAG CJTIS COF CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDU HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B LK8 LUGTX M27 M41 MO0 N4W N9A O-L O9- O9~ OAUVE OBH ODZKP OHH OHT OK0 OK1 OVD OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSI SSZ T5K TEORI TWZ UGJ UNMZH UV1 WH7 WOW WUQ X7M XFW YOC YQI YQJ Z5R ZGI ZXP ZY1 ~02 ~G- ~KM AACTN RIG AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7SS 7T5 H94 K9. NAPCQ |
| ID | FETCH-LOGICAL-c534t-b2421f9e42cdab002d63ce2eb5b6bcd85f911fec38d3521aa6034559c5e3d6cb3 |
| IEDL.DBID | .~1 |
| ISSN | 0091-6749 |
| IngestDate | Wed Aug 13 07:14:05 EDT 2025 Thu Apr 03 07:09:20 EDT 2025 Tue Jul 01 00:47:29 EDT 2025 Thu Apr 24 23:07:09 EDT 2025 Sun Apr 06 06:53:19 EDT 2025 Wed Apr 02 07:27:50 EDT 2025 Tue Aug 26 16:32:01 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | immune dysfunction infection Treg CNS IBD PML RA autoimmunity Biologics biologic response modifiers immunodeficiency CTLA-4 BRM |
| Language | English |
| License | Published by Elsevier Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c534t-b2421f9e42cdab002d63ce2eb5b6bcd85f911fec38d3521aa6034559c5e3d6cb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| OpenAccessLink | http://www.jacionline.org/article/S0091674917303354/pdf |
| PMID | 28263774 |
| PQID | 1895500885 |
| PQPubID | 105664 |
| PageCount | 12 |
| ParticipantIDs | proquest_journals_1895500885 pubmed_primary_28263774 crossref_citationtrail_10_1016_j_jaci_2017_02_013 crossref_primary_10_1016_j_jaci_2017_02_013 elsevier_sciencedirect_doi_10_1016_j_jaci_2017_02_013 elsevier_clinicalkeyesjournals_1_s2_0_S0091674917303354 elsevier_clinicalkey_doi_10_1016_j_jaci_2017_02_013 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-05-01 |
| PublicationDateYYYYMMDD | 2017-05-01 |
| PublicationDate_xml | – month: 05 year: 2017 text: 2017-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: St. Louis |
| PublicationTitle | Journal of allergy and clinical immunology |
| PublicationTitleAlternate | J Allergy Clin Immunol |
| PublicationYear | 2017 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Lipson, Drake (bib19) 2011; 17 Igarashi, Kato, Kato, Song, Nakagawa (bib29) 2012; 39 Schwab, Ulzheimer, Fox, Schneider-Hohendorf, Kieseier, Monoranu (bib65) 2012; 78 Arnold, Misbah (bib104) 2008; 358 Keane, Gershon, Wise, Mirabile-Levens, Kasznica, Schwieterman (bib87) 2001; 345 Brunasso, Aberer, Massone (bib51) 2014; 2014 Winkler, Jensen, Manzke, Schulz, Diehl, Engert (bib9) 1999; 94 Kremer (bib71) 2006; 144 Wells, Jodat, Schiff (bib83) 2014; 8 Weber, Kahler, Hauschild (bib18) 2012; 30 Leonardi, Kimball, Papp, Yeilding, Guzzo, Wang (bib78) 2008; 371 Bessissow, Renard, Hoffman, Vermeire, Rutgeerts, Van Assche (bib59) 2012; 36 Steinke, Platts-Mills, Commins (bib106) 2015; 135 Mastroianni (bib90) 2011; 17 Her, Kavanaugh (bib44) 2016; 137 Ramos-Casals, Perez-Alvarez, Perez-de-Lis, Xaubet, Bosch (bib101) 2011; 124 Vasquez, Fabrega, Pollak (bib8) 1995; 27 Hillmen, Muus, Röth, Elebute, Risitano, Schrezenmeier (bib45) 2013; 162 Donia, Pedersen, Svane (bib21) 2016 Agache, Akdis (bib114) 2016; 65 Stübgen (bib52) 2008; 37 Perez-Alvarez, Perez-de-Lis, Ramos-Casals (bib56) 2013; 25 Ortega, Liu, Pavord, Brusselle, FitzGerald, Chetta (bib118) 2014; 371 Griffiths, Strober, van de Kerkhof, Ho, Fidelus-Gort, Yeilding (bib79) 2010; 362 Ghosh, Chaki, Mandal (bib109) 2012; 31 Bachert, Zhang, Gevaert (bib125) 2015; 136 Baeten, Sieper, Braun, Baraliakos, Dougados, Emery (bib46) 2015; 373 Chinen, Notarangelo, Shearer (bib2) 2016; 138 Vincenti, Charpentier, Vanrenterghem, Rostaing, Bresnahan, Darji (bib33) 2010; 10 Quach, Hsu (bib47) 2016; 152 Kremer, Westhovens, Leon, Di Giorgio, Alten, Steinfeld (bib81) 2003; 349 Browne, Holland (bib5) 2010; 10 Damle, Doyle (bib67) 1989; 142 Kone-Paut, Galeotti (bib75) 2015; 11 Ramos-Casals, Brito-Zerón, Muñoz, Soria, Galiana, Bertolaccini (bib50) 2007; 86 Durrbach, Pestana, Pearson, Vincenti, Garcia, Campistol (bib34) 2010; 10 Berger, Koralnik (bib63) 2005; 353 Daïen, Morel (bib121) 2014; 2014 Flood-Page, Swenson, Faiferman, Matthews, Williams, Brannick (bib117) 2007; 176 Ramos-Casals, Roberto-Perez-Alvarez, Diaz-Lagares, Cuadrado, Khamashta (bib55) 2010; 9 Descotes, Vial (bib6) 2007 Weinblatt, Combe, Covucci, Aranda, Becker, Keystone (bib72) 2006; 54 Lee, Kavanaugh (bib43) 2005; 116 Fraser, Smith, Imrie, Meyer (bib36) 2007; 14 Utsunomiya, Choi, Chihara, Seto (bib25) 2015; 106 Morais, Vilas-Boas, Isenberg (bib41) 2015; 7 IL-2 package insert. Available at Schmidt-Arras, Rose-John (bib108) 2016; 64 Colombel, Sands, Rutgeerts, Sandborn, Danese, D'Haens (bib62) 2016 Lucas, Chandra, Nejentsev, Condliffe, Okkenhaug (bib111) 2016; 16 Jones, Peña-Sánchez (bib123) 2014; 43 Barmettler, Price (bib40) 2015; 136 Mastellos, Ricklin, Yancopoulou, Risitano, Lambris (bib96) 2014; 7 Bek, Nielsen, Bojesen, Franke, Bank, Vogel (bib124) 2016; 44 Rakhit, Yeon, Ferrante, Fettner, Nadeau, Motzer (bib69) 1999; 65 Hodi, O'Day, McDermott, Weber, Sosman, Haanen (bib17) 2010; 363 Zukiwski, David, Coan, Wallace, Gutterman, Mavligit (bib58) 1990; 65 Moiton, Richez, Dumoulin, Mehsen, Dehais, Schaeverbeke (bib89) 2006; 12 Lorenzini, Dotta, Giacomelli, Vairo, Badolato (bib112) 2017; 101 Dinarello, Simon, van der Meer (bib27) 2012; 11 Khasnis, Calabrese (bib53) 2010; 40 Thaçi, Blauvelt, Reich, Tsai, Vanaclocha, Kingo (bib99) 2015; 73 Maloney, Grillo-López, Bodkin, White, Liles, Royston (bib86) 1997; 15 Leonard, Sherman, Fisher, Buchanan, Larsen, Atkins (bib70) 1997; 90 Chung, Mirakhur, Chan, Le, Berlin, Morse (bib105) 2008; 358 Castro, Zangrilli, Wechsler, Bateman, Brusselle, Bardin (bib120) 2015; 3 Klatzmann, Abbas (bib113) 2015; 15 Malisiewicz, Murer, Pachlopnik Schmid, French, Schmid-Grendelmeier, Navarini (bib60) 2011; 223 Quirce, Bobolea, Dominguez-Ortega, Barranco (bib115) 2014; 50 Sims, Smith (bib74) 2010; 10 Kappos, Hartung, Freedman, Boyko, Radü, Mikol (bib102) 2014; 13 Saliu, Sofer, Stein, Schwander, Wallis (bib88) 2006; 194 Isenberg, Gordon, Licu, Copt, Rossi, Wofsy (bib42) 2015; 74 Rossi, Sgambato, De Chiara, Casaluce, Losanno, Sacco (bib23) 2016; 9 Schiff, Keiserman, Codding, Songcharoen, Berman, Nayiager (bib61) 2011; 70 Casrouge, Zhang, Eidenschenk, Jouanguy, Puel, Yang (bib73) 2006; 314 Brennan, Morton, Spindeldreher, Kiessling, Allenspach, Hey (bib10) 2010; 2 Hueber, Sands, Lewitzky, Vandemeulebroecke, Reinisch, Higgins (bib48) 2012; 61 Lebrec, Ponce, Preston, Iles, Born, Hooper (bib100) 2015; 31 Kerbleski, Gottlieb (bib3) 2009; 58 Fine, Sorbello, Kortepeter, Scarazzini (bib64) 2013; 57 Cantini, Niccoli, Nannini, Cassarà, Kaloudi, Giulio Favalli (bib122) 2016; 45 Boisson-Dupuis, Bustamante, El-Baghdadi, Camcioglu, Parvaneh, Azbaoui El (bib26) 2015; 264 Suntharalingam, Perry, Ward, Brett, Castello-Cortes, Brunner (bib14) 2006; 355 Weinblatt, Moreland, Westhovens, Cohen, Kelly, Khan (bib82) 2013; 40 Blauvelt, Prinz, Gottlieb, Kingo, Sofen, Ruer-Mulard (bib97) 2014; 172 Perez-Alvarez, Perez-de-Lis, Diaz-Lagares, Pego-Reigosa, Retamozo, Bove (bib57) 2011; 41 Schiff, Weinblatt, Valente, van der Heijde, Citera, Elegbe (bib31) 2014; 73 Grimbacher, Warnatz, Yong, Korganow, Peter (bib1) 2016; 137 Pavord, Korn, Howarth, Bleecker, Buhl, Keene (bib119) 2012; 380 Wong, Kavanagh (bib95) 2015; 165 Campbell, Chen, Bhagat, Parker, Ostor (bib92) 2011; 50 Robert, Thomas, Bondarenko, O'Day, Weber, Garbe (bib16) 2011; 364 McLaughlin, Grillo-López, Link, Levy, Czuczman, Williams (bib85) 1998; 16 Clarke (bib12) 2010; 196 Tsai, Ho, Song, Szapary, Guzzo, Shen (bib28) 2011; 63 Bustamante, Boisson-Dupuis, Abel, Casanova (bib80) 2014; 26 Wallis (bib91) 2009; 22 Casulo, Maragulia, Zelenetz (bib39) 2013; 13 Accessed October 25, 2016. de Golian, Kwong, Swetter, Pugliese (bib22) 2016; 17 Toussirot, Houvenagel, Goëb, Fouache, Martin, Le Dantec (bib4) 2012; 79 Papp, Langley, Lebwohl, Krueger, Szapary, Yeilding (bib77) 2008; 371 Simon, Hösli, Kostylina, Yawalkar, Simon (bib107) 2008; 121 Johnson, Balko, Compton, Chalkias, Gorham, Xu (bib20) 2016; 375 Papp, Griffiths, Gordon, Lebwohl, Szapary, Wasfi (bib49) 2013; 168 Czaja (bib54) 2011; 56 Cotran, Pober, Gimbrone, Springer, Wiebke, Gaspari (bib66) 1988; 140 Makatsori, Kiani-Alikhan, Manson, Verma, Leandro, Gurugama (bib37) 2014; 107 Genovese, Covarrubias, Leon, Mysler, Keiserman, Valente (bib30) 2011; 63 McInnes, Mease, Kirkham, Kavanaugh, Ritchlin, Rahman (bib98) 2015; 386 Bugelski, Achuthanandam, Capocasale, Treacy, Bouman-Thio (bib11) 2009; 5 Druey, Parikh (bib110) 2016 Galvão, Castells (bib103) 2015; 3 Wherry, Kurachi (bib15) 2015; 15 Abbas, Lichtman, Pillai (bib84) 2014 Wing (bib7) 2008; 5 Hünig (bib13) 2007 Vincenti, Rostaing, Grinyo, Rice, Steinberg, Gaite (bib32) 2016; 374 Kaplan, Kopyltsova, Khokhar, Lam, Bonagura (bib38) 2014; 2 Tanaka, Narazaki, Kishimoto (bib93) 2016; 8 Schejbel, Fadnes, Permin, Lappegård, Garred, Mollnes (bib94) 2013; 218 Fuji, Shindo (bib24) 2016; 3 Rostaing, Vincenti, Grinyó, Rice, Bresnahan, Steinberg (bib35) 2013; 13 Lachmann, Kone-Paut, Kuemmerle-Deschner, Leslie, Hachulla, Quartier (bib76) 2009; 360 Brightling, Berry, Amrani (bib116) 2008; 121 Fraser (10.1016/j.jaci.2017.02.013_bib36) 2007; 14 Jones (10.1016/j.jaci.2017.02.013_bib123) 2014; 43 Berger (10.1016/j.jaci.2017.02.013_bib63) 2005; 353 Kremer (10.1016/j.jaci.2017.02.013_bib81) 2003; 349 Bessissow (10.1016/j.jaci.2017.02.013_bib59) 2012; 36 Perez-Alvarez (10.1016/j.jaci.2017.02.013_bib57) 2011; 41 Simon (10.1016/j.jaci.2017.02.013_bib107) 2008; 121 Maloney (10.1016/j.jaci.2017.02.013_bib86) 1997; 15 Thaçi (10.1016/j.jaci.2017.02.013_bib99) 2015; 73 Flood-Page (10.1016/j.jaci.2017.02.013_bib117) 2007; 176 Donia (10.1016/j.jaci.2017.02.013_bib21) 2016 Cotran (10.1016/j.jaci.2017.02.013_bib66) 1988; 140 Wells (10.1016/j.jaci.2017.02.013_bib83) 2014; 8 Blauvelt (10.1016/j.jaci.2017.02.013_bib97) 2014; 172 Tanaka (10.1016/j.jaci.2017.02.013_bib93) 2016; 8 Brightling (10.1016/j.jaci.2017.02.013_bib116) 2008; 121 Schmidt-Arras (10.1016/j.jaci.2017.02.013_bib108) 2016; 64 Malisiewicz (10.1016/j.jaci.2017.02.013_bib60) 2011; 223 Chung (10.1016/j.jaci.2017.02.013_bib105) 2008; 358 Campbell (10.1016/j.jaci.2017.02.013_bib92) 2011; 50 Lucas (10.1016/j.jaci.2017.02.013_bib111) 2016; 16 Hueber (10.1016/j.jaci.2017.02.013_bib48) 2012; 61 Lorenzini (10.1016/j.jaci.2017.02.013_bib112) 2017; 101 Clarke (10.1016/j.jaci.2017.02.013_bib12) 2010; 196 Klatzmann (10.1016/j.jaci.2017.02.013_bib113) 2015; 15 Agache (10.1016/j.jaci.2017.02.013_bib114) 2016; 65 Browne (10.1016/j.jaci.2017.02.013_bib5) 2010; 10 Brennan (10.1016/j.jaci.2017.02.013_bib10) 2010; 2 Kone-Paut (10.1016/j.jaci.2017.02.013_bib75) 2015; 11 Boisson-Dupuis (10.1016/j.jaci.2017.02.013_bib26) 2015; 264 Kremer (10.1016/j.jaci.2017.02.013_bib71) 2006; 144 Ortega (10.1016/j.jaci.2017.02.013_bib118) 2014; 371 Fine (10.1016/j.jaci.2017.02.013_bib64) 2013; 57 Kerbleski (10.1016/j.jaci.2017.02.013_bib3) 2009; 58 Quach (10.1016/j.jaci.2017.02.013_bib47) 2016; 152 Galvão (10.1016/j.jaci.2017.02.013_bib103) 2015; 3 Igarashi (10.1016/j.jaci.2017.02.013_bib29) 2012; 39 Steinke (10.1016/j.jaci.2017.02.013_bib106) 2015; 135 Rostaing (10.1016/j.jaci.2017.02.013_bib35) 2013; 13 Weinblatt (10.1016/j.jaci.2017.02.013_bib82) 2013; 40 Kaplan (10.1016/j.jaci.2017.02.013_bib38) 2014; 2 Toussirot (10.1016/j.jaci.2017.02.013_bib4) 2012; 79 Descotes (10.1016/j.jaci.2017.02.013_bib6) 2007 Weber (10.1016/j.jaci.2017.02.013_bib18) 2012; 30 Hillmen (10.1016/j.jaci.2017.02.013_bib45) 2013; 162 Mastellos (10.1016/j.jaci.2017.02.013_bib96) 2014; 7 Pavord (10.1016/j.jaci.2017.02.013_bib119) 2012; 380 Mastroianni (10.1016/j.jaci.2017.02.013_bib90) 2011; 17 Hodi (10.1016/j.jaci.2017.02.013_bib17) 2010; 363 Vasquez (10.1016/j.jaci.2017.02.013_bib8) 1995; 27 Leonardi (10.1016/j.jaci.2017.02.013_bib78) 2008; 371 Daïen (10.1016/j.jaci.2017.02.013_bib121) 2014; 2014 Saliu (10.1016/j.jaci.2017.02.013_bib88) 2006; 194 Wing (10.1016/j.jaci.2017.02.013_bib7) 2008; 5 Winkler (10.1016/j.jaci.2017.02.013_bib9) 1999; 94 Bek (10.1016/j.jaci.2017.02.013_bib124) 2016; 44 Ramos-Casals (10.1016/j.jaci.2017.02.013_bib50) 2007; 86 Schiff (10.1016/j.jaci.2017.02.013_bib61) 2011; 70 Papp (10.1016/j.jaci.2017.02.013_bib49) 2013; 168 Papp (10.1016/j.jaci.2017.02.013_bib77) 2008; 371 Czaja (10.1016/j.jaci.2017.02.013_bib54) 2011; 56 Ramos-Casals (10.1016/j.jaci.2017.02.013_bib101) 2011; 124 Barmettler (10.1016/j.jaci.2017.02.013_bib40) 2015; 136 Quirce (10.1016/j.jaci.2017.02.013_bib115) 2014; 50 Dinarello (10.1016/j.jaci.2017.02.013_bib27) 2012; 11 McInnes (10.1016/j.jaci.2017.02.013_bib98) 2015; 386 Suntharalingam (10.1016/j.jaci.2017.02.013_bib14) 2006; 355 Cantini (10.1016/j.jaci.2017.02.013_bib122) 2016; 45 Hünig (10.1016/j.jaci.2017.02.013_bib13) 2007 Ramos-Casals (10.1016/j.jaci.2017.02.013_bib55) 2010; 9 Lachmann (10.1016/j.jaci.2017.02.013_bib76) 2009; 360 Wong (10.1016/j.jaci.2017.02.013_bib95) 2015; 165 Wallis (10.1016/j.jaci.2017.02.013_bib91) 2009; 22 Durrbach (10.1016/j.jaci.2017.02.013_bib34) 2010; 10 Schwab (10.1016/j.jaci.2017.02.013_bib65) 2012; 78 Bugelski (10.1016/j.jaci.2017.02.013_bib11) 2009; 5 Leonard (10.1016/j.jaci.2017.02.013_bib70) 1997; 90 Johnson (10.1016/j.jaci.2017.02.013_bib20) 2016; 375 Keane (10.1016/j.jaci.2017.02.013_bib87) 2001; 345 Isenberg (10.1016/j.jaci.2017.02.013_bib42) 2015; 74 Vincenti (10.1016/j.jaci.2017.02.013_bib33) 2010; 10 Khasnis (10.1016/j.jaci.2017.02.013_bib53) 2010; 40 Robert (10.1016/j.jaci.2017.02.013_bib16) 2011; 364 Druey (10.1016/j.jaci.2017.02.013_bib110) 2016 Schejbel (10.1016/j.jaci.2017.02.013_bib94) 2013; 218 Abbas (10.1016/j.jaci.2017.02.013_bib84) 2014 Lee (10.1016/j.jaci.2017.02.013_bib43) 2005; 116 Wherry (10.1016/j.jaci.2017.02.013_bib15) 2015; 15 Makatsori (10.1016/j.jaci.2017.02.013_bib37) 2014; 107 Damle (10.1016/j.jaci.2017.02.013_bib67) 1989; 142 Rakhit (10.1016/j.jaci.2017.02.013_bib69) 1999; 65 Arnold (10.1016/j.jaci.2017.02.013_bib104) 2008; 358 Lipson (10.1016/j.jaci.2017.02.013_bib19) 2011; 17 Vincenti (10.1016/j.jaci.2017.02.013_bib32) 2016; 374 Brunasso (10.1016/j.jaci.2017.02.013_bib51) 2014; 2014 Stübgen (10.1016/j.jaci.2017.02.013_bib52) 2008; 37 Sims (10.1016/j.jaci.2017.02.013_bib74) 2010; 10 Casrouge (10.1016/j.jaci.2017.02.013_bib73) 2006; 314 Rossi (10.1016/j.jaci.2017.02.013_bib23) 2016; 9 Perez-Alvarez (10.1016/j.jaci.2017.02.013_bib56) 2013; 25 Castro (10.1016/j.jaci.2017.02.013_bib120) 2015; 3 Chinen (10.1016/j.jaci.2017.02.013_bib2) 2016; 138 Weinblatt (10.1016/j.jaci.2017.02.013_bib72) 2006; 54 Morais (10.1016/j.jaci.2017.02.013_bib41) 2015; 7 Bustamante (10.1016/j.jaci.2017.02.013_bib80) 2014; 26 Moiton (10.1016/j.jaci.2017.02.013_bib89) 2006; 12 de Golian (10.1016/j.jaci.2017.02.013_bib22) 2016; 17 Schiff (10.1016/j.jaci.2017.02.013_bib31) 2014; 73 Ghosh (10.1016/j.jaci.2017.02.013_bib109) 2012; 31 Kappos (10.1016/j.jaci.2017.02.013_bib102) 2014; 13 Utsunomiya (10.1016/j.jaci.2017.02.013_bib25) 2015; 106 Her (10.1016/j.jaci.2017.02.013_bib44) 2016; 137 10.1016/j.jaci.2017.02.013_bib68 Fuji (10.1016/j.jaci.2017.02.013_bib24) 2016; 3 Genovese (10.1016/j.jaci.2017.02.013_bib30) 2011; 63 Tsai (10.1016/j.jaci.2017.02.013_bib28) 2011; 63 Baeten (10.1016/j.jaci.2017.02.013_bib46) 2015; 373 Colombel (10.1016/j.jaci.2017.02.013_bib62) 2016 Bachert (10.1016/j.jaci.2017.02.013_bib125) 2015; 136 Lebrec (10.1016/j.jaci.2017.02.013_bib100) 2015; 31 Grimbacher (10.1016/j.jaci.2017.02.013_bib1) 2016; 137 Casulo (10.1016/j.jaci.2017.02.013_bib39) 2013; 13 Griffiths (10.1016/j.jaci.2017.02.013_bib79) 2010; 362 McLaughlin (10.1016/j.jaci.2017.02.013_bib85) 1998; 16 Zukiwski (10.1016/j.jaci.2017.02.013_bib58) 1990; 65 |
| References_xml | – volume: 9 start-page: 188 year: 2010 end-page: 193 ident: bib55 article-title: Autoimmune diseases induced by biological agents: a double-edged sword? publication-title: Autoimmun Rev – volume: 73 start-page: 86 year: 2014 end-page: 94 ident: bib31 article-title: Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial publication-title: Ann Rheum Dis – volume: 40 start-page: 787 year: 2013 end-page: 797 ident: bib82 article-title: Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the Abatacept Clinical Trial Program publication-title: J Rheumatol – volume: 353 start-page: 414 year: 2005 end-page: 416 ident: bib63 article-title: Progressive Multifocal leukoencephalopathy and natalizumab—unforeseen consequences publication-title: N Engl J Med – volume: 50 start-page: 355 year: 2014 end-page: 361 ident: bib115 article-title: Future biologic therapies in asthma publication-title: Arch Bronconeumol – reference: . Accessed October 25, 2016. – volume: 13 start-page: 353 year: 2014 end-page: 363 ident: bib102 article-title: Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial publication-title: Lancet Neurol – year: 2016 ident: bib110 article-title: Idiopathic systemic capillary leak syndrome (Clarkson disease) publication-title: J Allergy Clin Immunol – volume: 22 start-page: 403 year: 2009 end-page: 409 ident: bib91 article-title: Infectious complications of tumor necrosis factor blockade publication-title: Curr Opin Infect Dis – volume: 345 start-page: 1098 year: 2001 end-page: 1104 ident: bib87 article-title: Tuberculosis associated with infliximab, a tumor necrosis factor α–neutralizing agent publication-title: N Engl J Med – volume: 16 start-page: 702 year: 2016 end-page: 714 ident: bib111 article-title: PI3Kδ and primary immunodeficiencies publication-title: Nat Rev Immunol – volume: 165 start-page: 306 year: 2015 end-page: 320 ident: bib95 article-title: Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome publication-title: Transl Res – volume: 7 start-page: 122 year: 2015 end-page: 151 ident: bib41 article-title: B-cell survival factors in autoimmune rheumatic disorders publication-title: Ther Adv Musculoskelet Dis – volume: 136 start-page: 1407 year: 2015 end-page: 1409 ident: bib40 article-title: Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long? publication-title: J Allergy Clin Immunol – volume: 94 start-page: 2217 year: 1999 end-page: 2224 ident: bib9 article-title: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) publication-title: Blood – volume: 101 start-page: 29 year: 2017 end-page: 38 ident: bib112 article-title: STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases publication-title: J Leukoc Biol – volume: 54 start-page: 2807 year: 2006 end-page: 2816 ident: bib72 article-title: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study publication-title: Arthritis Rheum – volume: 65 start-page: 1521 year: 1990 end-page: 1524 ident: bib58 article-title: Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration publication-title: Cancer – volume: 2014 start-page: 179180 year: 2014 ident: bib51 article-title: New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review publication-title: ScientificWorldJournal – start-page: 193 year: 2007 end-page: 204 ident: bib6 article-title: Flu-like syndrome and cytokines. In: Cytokines in human health – volume: 3 start-page: 175 year: 2015 end-page: 185 ident: bib103 article-title: Hypersensitivity to biological agents—updated diagnosis, management, and treatment publication-title: J Allergy Clin Immunol Pract – volume: 15 start-page: 283 year: 2015 end-page: 294 ident: bib113 article-title: The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases publication-title: Nat Rev Immunol – volume: 58 start-page: 1033 year: 2009 end-page: 1039 ident: bib3 article-title: Dermatological complications and safety of anti-TNF treatments publication-title: Gut – volume: 2 start-page: 233 year: 2010 end-page: 255 ident: bib10 article-title: Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies publication-title: MAbs – volume: 25 start-page: 56 year: 2013 end-page: 64 ident: bib56 article-title: Biologics-induced autoimmune diseases publication-title: Curr Opin Rheumatol – volume: 39 start-page: 242 year: 2012 end-page: 252 ident: bib29 article-title: Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial publication-title: J Dermatol – volume: 358 start-page: 2735 year: 2008 end-page: 2736 ident: bib104 article-title: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose publication-title: N Engl J Med – volume: 40 start-page: 147 year: 2010 end-page: 163 ident: bib53 article-title: Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk publication-title: Semin Arthritis Rheum – volume: 86 start-page: 242 year: 2007 end-page: 251 ident: bib50 article-title: Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases publication-title: Medicine – volume: 7 start-page: 583 year: 2014 end-page: 598 ident: bib96 article-title: Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape publication-title: Expert Rev Hematol – volume: 90 start-page: 2541 year: 1997 end-page: 2548 ident: bib70 article-title: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production publication-title: Blood – volume: 44 start-page: 554 year: 2016 end-page: 567 ident: bib124 article-title: Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases publication-title: Aliment Pharmacol Ther – volume: 172 start-page: 484 year: 2014 end-page: 493 ident: bib97 article-title: Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis publication-title: Br J Dermatol – volume: 371 start-page: 1198 year: 2014 end-page: 1207 ident: bib118 article-title: Mepolizumab treatment in patients with severe eosinophilic asthma publication-title: N Engl J Med – reference: IL-2 package insert. Available at: – volume: 194 start-page: 486 year: 2006 end-page: 492 ident: bib88 article-title: Tumor necrosis factor blockers: differential effects on mycobacterial immunity publication-title: J Infect Dis – volume: 45 start-page: 519 year: 2016 end-page: 532 ident: bib122 article-title: Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis publication-title: Semin Arthritis Rheum – volume: 364 start-page: 2517 year: 2011 end-page: 2526 ident: bib16 article-title: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma publication-title: N Engl J Med – year: 2016 ident: bib62 article-title: The safety of vedolizumab for ulcerative colitis and Crohn's disease publication-title: Gut – volume: 17 start-page: 57 year: 2016 ident: bib22 article-title: Cutaneous complications of targeted melanoma therapy publication-title: Curr Treat Options Oncol – volume: 57 start-page: 849 year: 2013 end-page: 852 ident: bib64 article-title: Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients publication-title: Clin Infect Dis – volume: 61 start-page: 1693 year: 2012 end-page: 1700 ident: bib48 article-title: Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial publication-title: Gut – year: 2016 ident: bib21 article-title: Cancer immunotherapy in patients with preexisting autoimmune disorders publication-title: Semin Immunopathol – volume: 31 start-page: 557 year: 2015 end-page: 574 ident: bib100 article-title: Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk publication-title: Curr Med Res Opin – volume: 374 start-page: 333 year: 2016 end-page: 343 ident: bib32 article-title: Belatacept and long-term outcomes in kidney transplantation publication-title: N Engl J Med – volume: 136 start-page: 1431 year: 2015 end-page: 1441 ident: bib125 article-title: Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis publication-title: J Allergy Clin Immunol – volume: 138 start-page: 1531 year: 2016 end-page: 1540 ident: bib2 article-title: Advances in clinical immunology in 2015 publication-title: J Allergy Clin Immunol – volume: 264 start-page: 103 year: 2015 end-page: 120 ident: bib26 article-title: Inherited and acquired immunodeficiencies underlying tuberculosis in childhood publication-title: Immunol Rev – volume: 137 start-page: 19 year: 2016 end-page: 27 ident: bib44 article-title: Alterations in immune function with biologic therapies for autoimmune disease publication-title: J Allergy Clin Immunol – volume: 74 start-page: 2006 year: 2015 end-page: 2015 ident: bib42 article-title: Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial) publication-title: Ann Rheum Dis – volume: 13 start-page: 106 year: 2013 end-page: 111 ident: bib39 article-title: Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections publication-title: Clin Lymphoma Myeloma Leuk – volume: 137 start-page: 3 year: 2016 end-page: 18 ident: bib1 article-title: The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects publication-title: J Allergy Clin Immunol – volume: 14 start-page: 96 year: 2007 end-page: 109 ident: bib36 article-title: Hematology Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Alemtuzumab in chronic lymphocytic leukemia publication-title: Curr Oncol – volume: 26 start-page: 454 year: 2014 end-page: 470 ident: bib80 article-title: Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity publication-title: Semin Immunol – volume: 362 start-page: 118 year: 2010 end-page: 128 ident: bib79 article-title: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis publication-title: N Engl J Med – volume: 41 start-page: 256 year: 2011 end-page: 264 ident: bib57 article-title: Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases publication-title: Semin Arthritis Rheum – volume: 314 start-page: 308 year: 2006 end-page: 312 ident: bib73 article-title: Herpes simplex virus encephalitis in human UNC-93B deficiency publication-title: Science – volume: 363 start-page: 711 year: 2010 end-page: 723 ident: bib17 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N Engl J Med – volume: 65 start-page: 243 year: 2016 end-page: 252 ident: bib114 article-title: Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine publication-title: Allergol Int – volume: 373 start-page: 2534 year: 2015 end-page: 2548 ident: bib46 article-title: Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis publication-title: N Engl J Med – volume: 107 start-page: 821 year: 2014 end-page: 828 ident: bib37 article-title: Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes publication-title: QJM – volume: 176 start-page: 1062 year: 2007 end-page: 1071 ident: bib117 article-title: A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma publication-title: Am J Respir Crit Care Med – volume: 2014 start-page: 1 year: 2014 end-page: 11 ident: bib121 article-title: Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine publication-title: Mediators Inflamm – volume: 2 start-page: 594 year: 2014 end-page: 600 ident: bib38 article-title: Rituximab and immune deficiency: case series and review of the literature publication-title: J Allergy Clin Immunol Pract – volume: 13 start-page: 2875 year: 2013 end-page: 2883 ident: bib35 article-title: Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study publication-title: Am J Transplant – volume: 360 start-page: 2416 year: 2009 end-page: 2425 ident: bib76 article-title: Use of canakinumab in the cryopyrin-associated periodic syndrome publication-title: N Engl J Med – volume: 10 start-page: 534 year: 2010 end-page: 541 ident: bib5 article-title: Immunodeficiency secondary to anticytokine autoantibodies publication-title: Curr Opin Allergy Clin Immunol – volume: 11 start-page: 1083 year: 2015 end-page: 1092 ident: bib75 article-title: Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome publication-title: Expert Rev Clin Immunol – year: 2014 ident: bib84 article-title: Cellular and molecular immunology – volume: 375 start-page: 1749 year: 2016 end-page: 1755 ident: bib20 article-title: Fulminant myocarditis with combination immune checkpoint blockade publication-title: N Engl J Med – volume: 349 start-page: 1907 year: 2003 end-page: 1915 ident: bib81 article-title: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig publication-title: N Engl J Med – volume: 63 start-page: 2854 year: 2011 end-page: 2864 ident: bib30 article-title: Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate publication-title: Arthritis Rheum – volume: 79 start-page: 457 year: 2012 end-page: 463 ident: bib4 article-title: Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series publication-title: Joint Bone Spine – volume: 144 start-page: 865 year: 2006 ident: bib71 article-title: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis publication-title: Ann Intern Med – volume: 78 start-page: 458 year: 2012 end-page: 467 ident: bib65 article-title: Fatal PML associated with efalizumab therapy: insights into integrin L 2 in JC virus control publication-title: Neurology – volume: 15 start-page: 3266 year: 1997 end-page: 3274 ident: bib86 article-title: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma publication-title: J Clin Oncol – volume: 10 start-page: 547 year: 2010 end-page: 557 ident: bib34 article-title: A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study) publication-title: Am J Transplant – volume: 196 start-page: 453 year: 2010 end-page: 474 ident: bib12 article-title: Mechanisms of adverse drug reactions to biologics publication-title: Handb Exp Pharmacol – volume: 17 start-page: 6958 year: 2011 end-page: 6962 ident: bib19 article-title: Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma publication-title: Clin Cancer Res – volume: 223 start-page: 311 year: 2011 end-page: 315 ident: bib60 article-title: Eosinophilia during psoriasis treatment with TNF antagonists publication-title: Dermatology – volume: 142 start-page: 2660 year: 1989 end-page: 2669 ident: bib67 article-title: IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome publication-title: J Immunol – volume: 70 start-page: 2003 year: 2011 end-page: 2007 ident: bib61 article-title: Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study publication-title: Ann Rheum Dis – volume: 355 start-page: 1018 year: 2006 end-page: 1028 ident: bib14 article-title: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 publication-title: N Engl J Med – volume: 8 start-page: 41 year: 2014 end-page: 55 ident: bib83 article-title: A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations publication-title: Biologics – volume: 121 start-page: 5 year: 2008 end-page: 10 ident: bib116 article-title: Targeting TNF-α: a novel therapeutic approach for asthma publication-title: J Allergy Clin Immunol – volume: 50 start-page: 552 year: 2011 end-page: 562 ident: bib92 article-title: Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials publication-title: Rheumatology – volume: 135 start-page: 589 year: 2015 end-page: 596 ident: bib106 article-title: The alpha-gal story: Lessons learned from connecting the dots publication-title: J Allergy Clin Immunol – volume: 8 start-page: 959 year: 2016 end-page: 970 ident: bib93 article-title: Immunotherapeutic implications of IL-6 blockade for cytokine storm publication-title: Immunotherapy – start-page: 111 year: 2007 end-page: 148 ident: bib13 article-title: Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies – volume: 17 start-page: 3881 year: 2011 end-page: 3887 ident: bib90 article-title: Current trends in management of hepatitis B virus reactivation in the biologic therapy era publication-title: World J Gastroenterol – volume: 358 start-page: 1109 year: 2008 end-page: 1117 ident: bib105 article-title: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose publication-title: N Engl J Med – volume: 218 start-page: 1304 year: 2013 end-page: 1310 ident: bib94 article-title: Primary complement C5 deficiencies—Molecular characterization and clinical review of two families publication-title: Immunobiology – volume: 36 start-page: 312 year: 2012 end-page: 323 ident: bib59 article-title: Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy publication-title: Aliment Pharmacol Ther – volume: 371 start-page: 1675 year: 2008 end-page: 1684 ident: bib77 article-title: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) publication-title: Lancet – volume: 10 start-page: 117 year: 2010 ident: bib74 article-title: The IL-1 family: regulators of immunity publication-title: Nat Rev Immunol – volume: 152 start-page: 486 year: 2016 ident: bib47 article-title: Perianal dermatophytosis during secukinumab therapy for plaque psoriasis publication-title: JAMA Dermatol – volume: 9 start-page: 419 year: 2016 end-page: 428 ident: bib23 article-title: Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer publication-title: Expert Rev Clin Pharmacol – volume: 168 start-page: 844 year: 2013 end-page: 854 ident: bib49 article-title: Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 publication-title: Br J Dermatol – volume: 3 start-page: 355 year: 2015 end-page: 366 ident: bib120 article-title: Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials publication-title: Lancet Respir Med – volume: 3 start-page: 70 year: 2016 ident: bib24 article-title: Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma publication-title: Stem Cell Investig – volume: 16 start-page: 2825 year: 1998 end-page: 2833 ident: bib85 article-title: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program publication-title: J Clin Oncol – volume: 64 start-page: 1403 year: 2016 end-page: 1415 ident: bib108 article-title: IL-6 pathway in the liver: From physiopathology to therapy publication-title: J Hepatol – volume: 5 start-page: 11 year: 2008 end-page: 15 ident: bib7 article-title: Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction publication-title: J Immunotoxicol – volume: 140 start-page: 1883 year: 1988 end-page: 1888 ident: bib66 article-title: Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome publication-title: J Immunol – volume: 65 start-page: 615 year: 1999 end-page: 629 ident: bib69 article-title: Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this “adaptive response” in mice publication-title: Clin Pharmacol Ther – volume: 371 start-page: 1665 year: 2008 end-page: 1674 ident: bib78 article-title: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) publication-title: Lancet – volume: 63 start-page: 154 year: 2011 end-page: 163 ident: bib28 article-title: Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL) publication-title: J Dermatol Sci – volume: 11 start-page: 633 year: 2012 end-page: 652 ident: bib27 article-title: Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases publication-title: Nat Rev Drug Discov – volume: 386 start-page: 1137 year: 2015 end-page: 1146 ident: bib98 article-title: Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet – volume: 15 start-page: 486 year: 2015 end-page: 499 ident: bib15 article-title: Molecular and cellular insights into T cell exhaustion publication-title: Nat Rev Immunol – volume: 5 start-page: 499 year: 2009 end-page: 521 ident: bib11 article-title: Monoclonal antibody-induced cytokine-release syndrome publication-title: Expert Rev Clin Immunol – volume: 124 start-page: 386 year: 2011 end-page: 394 ident: bib101 article-title: BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases publication-title: Am J Med – volume: 121 start-page: 122 year: 2008 end-page: 128 ident: bib107 article-title: Anti-CD20 (rituximab) treatment improves atopic eczema publication-title: J Allergy Clin Immunol – volume: 37 start-page: 281 year: 2008 end-page: 292 ident: bib52 article-title: Tumor necrosis factor-alpha antagonists and neuropathy publication-title: Muscle Nerve – volume: 27 start-page: 873 year: 1995 end-page: 874 ident: bib8 article-title: OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity publication-title: Transplant Proc – volume: 162 start-page: 62 year: 2013 end-page: 73 ident: bib45 article-title: Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria publication-title: Br J Haematol – volume: 73 start-page: 400 year: 2015 end-page: 409 ident: bib99 article-title: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial publication-title: J Am Acad Dermatol – volume: 30 start-page: 2691 year: 2012 end-page: 2697 ident: bib18 article-title: Management of immune-related adverse events and kinetics of response with ipilimumab publication-title: J Clin Oncol – volume: 43 start-page: 425 year: 2014 end-page: 440 ident: bib123 article-title: Who should receive biologic therapy for IBD? publication-title: Gastroenterol Clin North Am – volume: 56 start-page: 958 year: 2011 end-page: 976 ident: bib54 article-title: Drug-induced autoimmune-like hepatitis publication-title: Dig Dis Sci – volume: 380 start-page: 651 year: 2012 end-page: 659 ident: bib119 article-title: Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial publication-title: Lancet – volume: 106 start-page: 344 year: 2015 end-page: 351 ident: bib25 article-title: Recent advances in the treatment of adult T-cell leukemia-lymphomas publication-title: Cancer Sci – volume: 31 start-page: 410 year: 2012 end-page: 427 ident: bib109 article-title: Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease publication-title: Int Rev Immunol – volume: 12 start-page: 1151 year: 2006 end-page: 1153 ident: bib89 article-title: Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections publication-title: Clin Microbiol Infect – volume: 116 start-page: 900 year: 2005 end-page: 905 ident: bib43 article-title: Adverse reactions to biologic agents: focus on autoimmune disease therapies publication-title: J Allergy Clin Immunol – volume: 10 start-page: 535 year: 2010 end-page: 546 ident: bib33 article-title: A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study) publication-title: Am J Transplant – volume: 107 start-page: 821 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib37 article-title: Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes publication-title: QJM doi: 10.1093/qjmed/hcu094 – volume: 26 start-page: 454 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib80 article-title: Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity publication-title: Semin Immunol doi: 10.1016/j.smim.2014.09.008 – volume: 11 start-page: 633 year: 2012 ident: 10.1016/j.jaci.2017.02.013_bib27 article-title: Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3800 – volume: 30 start-page: 2691 year: 2012 ident: 10.1016/j.jaci.2017.02.013_bib18 article-title: Management of immune-related adverse events and kinetics of response with ipilimumab publication-title: J Clin Oncol doi: 10.1200/JCO.2012.41.6750 – volume: 3 start-page: 175 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib103 article-title: Hypersensitivity to biological agents—updated diagnosis, management, and treatment publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2014.12.006 – volume: 3 start-page: 70 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib24 article-title: Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma publication-title: Stem Cell Investig doi: 10.21037/sci.2016.09.13 – volume: 15 start-page: 283 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib113 article-title: The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases publication-title: Nat Rev Immunol doi: 10.1038/nri3823 – volume: 121 start-page: 5 year: 2008 ident: 10.1016/j.jaci.2017.02.013_bib116 article-title: Targeting TNF-α: a novel therapeutic approach for asthma publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2007.10.028 – volume: 13 start-page: 106 year: 2013 ident: 10.1016/j.jaci.2017.02.013_bib39 article-title: Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections publication-title: Clin Lymphoma Myeloma Leuk doi: 10.1016/j.clml.2012.11.011 – volume: 172 start-page: 484 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib97 article-title: Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis publication-title: Br J Dermatol doi: 10.1111/bjd.13348 – volume: 13 start-page: 2875 year: 2013 ident: 10.1016/j.jaci.2017.02.013_bib35 article-title: Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study publication-title: Am J Transplant doi: 10.1111/ajt.12460 – volume: 168 start-page: 844 year: 2013 ident: 10.1016/j.jaci.2017.02.013_bib49 article-title: Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5years of follow-up publication-title: Br J Dermatol doi: 10.1111/bjd.12214 – volume: 65 start-page: 615 year: 1999 ident: 10.1016/j.jaci.2017.02.013_bib69 article-title: Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this “adaptive response” in mice publication-title: Clin Pharmacol Ther doi: 10.1016/S0009-9236(99)90083-8 – volume: 375 start-page: 1749 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib20 article-title: Fulminant myocarditis with combination immune checkpoint blockade publication-title: N Engl J Med doi: 10.1056/NEJMoa1609214 – volume: 106 start-page: 344 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib25 article-title: Recent advances in the treatment of adult T-cell leukemia-lymphomas publication-title: Cancer Sci doi: 10.1111/cas.12617 – volume: 380 start-page: 651 year: 2012 ident: 10.1016/j.jaci.2017.02.013_bib119 article-title: Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(12)60988-X – volume: 63 start-page: 154 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib28 article-title: Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL) publication-title: J Dermatol Sci doi: 10.1016/j.jdermsci.2011.05.005 – volume: 371 start-page: 1675 year: 2008 ident: 10.1016/j.jaci.2017.02.013_bib77 article-title: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) publication-title: Lancet doi: 10.1016/S0140-6736(08)60726-6 – volume: 44 start-page: 554 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib124 article-title: Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13736 – volume: 142 start-page: 2660 year: 1989 ident: 10.1016/j.jaci.2017.02.013_bib67 article-title: IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome publication-title: J Immunol doi: 10.4049/jimmunol.142.8.2660 – volume: 17 start-page: 3881 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib90 article-title: Current trends in management of hepatitis B virus reactivation in the biologic therapy era publication-title: World J Gastroenterol doi: 10.3748/wjg.v17.i34.3881 – volume: 78 start-page: 458 year: 2012 ident: 10.1016/j.jaci.2017.02.013_bib65 article-title: Fatal PML associated with efalizumab therapy: insights into integrin L 2 in JC virus control publication-title: Neurology doi: 10.1212/WNL.0b013e3182478d4b – volume: 2 start-page: 233 year: 2010 ident: 10.1016/j.jaci.2017.02.013_bib10 article-title: Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies publication-title: MAbs doi: 10.4161/mabs.2.3.11782 – volume: 17 start-page: 57 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib22 article-title: Cutaneous complications of targeted melanoma therapy publication-title: Curr Treat Options Oncol doi: 10.1007/s11864-016-0434-0 – volume: 196 start-page: 453 year: 2010 ident: 10.1016/j.jaci.2017.02.013_bib12 article-title: Mechanisms of adverse drug reactions to biologics publication-title: Handb Exp Pharmacol doi: 10.1007/978-3-642-00663-0_16 – volume: 137 start-page: 3 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib1 article-title: The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2015.11.004 – volume: 116 start-page: 900 year: 2005 ident: 10.1016/j.jaci.2017.02.013_bib43 article-title: Adverse reactions to biologic agents: focus on autoimmune disease therapies publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2005.03.028 – volume: 65 start-page: 1521 year: 1990 ident: 10.1016/j.jaci.2017.02.013_bib58 article-title: Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration publication-title: Cancer doi: 10.1002/1097-0142(19900401)65:7<1521::AID-CNCR2820650712>3.0.CO;2-Y – volume: 10 start-page: 117 year: 2010 ident: 10.1016/j.jaci.2017.02.013_bib74 article-title: The IL-1 family: regulators of immunity publication-title: Nat Rev Immunol doi: 10.1038/nri2691 – ident: 10.1016/j.jaci.2017.02.013_bib68 – volume: 45 start-page: 519 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib122 article-title: Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2015.10.001 – volume: 121 start-page: 122 year: 2008 ident: 10.1016/j.jaci.2017.02.013_bib107 article-title: Anti-CD20 (rituximab) treatment improves atopic eczema publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2007.11.016 – year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib110 article-title: Idiopathic systemic capillary leak syndrome (Clarkson disease) publication-title: J Allergy Clin Immunol – volume: 176 start-page: 1062 year: 2007 ident: 10.1016/j.jaci.2017.02.013_bib117 article-title: A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200701-085OC – volume: 22 start-page: 403 year: 2009 ident: 10.1016/j.jaci.2017.02.013_bib91 article-title: Infectious complications of tumor necrosis factor blockade publication-title: Curr Opin Infect Dis doi: 10.1097/QCO.0b013e32832dda55 – year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib62 article-title: The safety of vedolizumab for ulcerative colitis and Crohn's disease publication-title: Gut – volume: 144 start-page: 865 year: 2006 ident: 10.1016/j.jaci.2017.02.013_bib71 article-title: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis publication-title: Ann Intern Med doi: 10.7326/0003-4819-144-12-200606200-00003 – volume: 101 start-page: 29 year: 2017 ident: 10.1016/j.jaci.2017.02.013_bib112 article-title: STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases publication-title: J Leukoc Biol doi: 10.1189/jlb.5RI0516-237RR – volume: 194 start-page: 486 year: 2006 ident: 10.1016/j.jaci.2017.02.013_bib88 article-title: Tumor necrosis factor blockers: differential effects on mycobacterial immunity publication-title: J Infect Dis doi: 10.1086/505430 – volume: 10 start-page: 547 year: 2010 ident: 10.1016/j.jaci.2017.02.013_bib34 article-title: A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study) publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2010.03016.x – volume: 8 start-page: 959 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib93 article-title: Immunotherapeutic implications of IL-6 blockade for cytokine storm publication-title: Immunotherapy doi: 10.2217/imt-2016-0020 – volume: 8 start-page: 41 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib83 article-title: A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations publication-title: Biologics – volume: 63 start-page: 2854 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib30 article-title: Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate publication-title: Arthritis Rheum doi: 10.1002/art.30463 – volume: 264 start-page: 103 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib26 article-title: Inherited and acquired immunodeficiencies underlying tuberculosis in childhood publication-title: Immunol Rev doi: 10.1111/imr.12272 – volume: 364 start-page: 2517 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib16 article-title: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1104621 – volume: 140 start-page: 1883 year: 1988 ident: 10.1016/j.jaci.2017.02.013_bib66 article-title: Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome publication-title: J Immunol doi: 10.4049/jimmunol.140.6.1883 – volume: 13 start-page: 353 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib102 article-title: Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(14)70028-6 – volume: 362 start-page: 118 year: 2010 ident: 10.1016/j.jaci.2017.02.013_bib79 article-title: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis publication-title: N Engl J Med doi: 10.1056/NEJMoa0810652 – volume: 7 start-page: 583 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib96 article-title: Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape publication-title: Expert Rev Hematol doi: 10.1586/17474086.2014.953926 – volume: 40 start-page: 787 year: 2013 ident: 10.1016/j.jaci.2017.02.013_bib82 article-title: Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the Abatacept Clinical Trial Program publication-title: J Rheumatol doi: 10.3899/jrheum.120906 – volume: 373 start-page: 2534 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib46 article-title: Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis publication-title: N Engl J Med doi: 10.1056/NEJMoa1505066 – volume: 25 start-page: 56 year: 2013 ident: 10.1016/j.jaci.2017.02.013_bib56 article-title: Biologics-induced autoimmune diseases publication-title: Curr Opin Rheumatol doi: 10.1097/BOR.0b013e32835b1366 – volume: 136 start-page: 1431 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib125 article-title: Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2015.10.010 – volume: 64 start-page: 1403 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib108 article-title: IL-6 pathway in the liver: From physiopathology to therapy publication-title: J Hepatol doi: 10.1016/j.jhep.2016.02.004 – volume: 73 start-page: 86 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib31 article-title: Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-203843 – volume: 137 start-page: 19 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib44 article-title: Alterations in immune function with biologic therapies for autoimmune disease publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2015.10.023 – volume: 11 start-page: 1083 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib75 article-title: Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome publication-title: Expert Rev Clin Immunol doi: 10.1586/1744666X.2015.1077702 – volume: 43 start-page: 425 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib123 article-title: Who should receive biologic therapy for IBD? publication-title: Gastroenterol Clin North Am doi: 10.1016/j.gtc.2014.05.004 – volume: 12 start-page: 1151 year: 2006 ident: 10.1016/j.jaci.2017.02.013_bib89 article-title: Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2006.01546.x – volume: 135 start-page: 589 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib106 article-title: The alpha-gal story: Lessons learned from connecting the dots publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.12.1947 – volume: 349 start-page: 1907 year: 2003 ident: 10.1016/j.jaci.2017.02.013_bib81 article-title: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig publication-title: N Engl J Med doi: 10.1056/NEJMoa035075 – volume: 358 start-page: 1109 year: 2008 ident: 10.1016/j.jaci.2017.02.013_bib105 article-title: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose publication-title: N Engl J Med doi: 10.1056/NEJMoa074943 – volume: 2014 start-page: 179180 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib51 article-title: New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review publication-title: ScientificWorldJournal doi: 10.1155/2014/179180 – volume: 36 start-page: 312 year: 2012 ident: 10.1016/j.jaci.2017.02.013_bib59 article-title: Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2012.05189.x – volume: 5 start-page: 11 year: 2008 ident: 10.1016/j.jaci.2017.02.013_bib7 article-title: Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction publication-title: J Immunotoxicol doi: 10.1080/15476910801897433 – volume: 73 start-page: 400 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib99 article-title: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2015.05.013 – volume: 10 start-page: 534 year: 2010 ident: 10.1016/j.jaci.2017.02.013_bib5 article-title: Immunodeficiency secondary to anticytokine autoantibodies publication-title: Curr Opin Allergy Clin Immunol doi: 10.1097/ACI.0b013e3283402b41 – volume: 86 start-page: 242 year: 2007 ident: 10.1016/j.jaci.2017.02.013_bib50 article-title: Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases publication-title: Medicine doi: 10.1097/MD.0b013e3181441a68 – volume: 165 start-page: 306 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib95 article-title: Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome publication-title: Transl Res doi: 10.1016/j.trsl.2014.10.010 – volume: 50 start-page: 552 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib92 article-title: Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials publication-title: Rheumatology doi: 10.1093/rheumatology/keq343 – volume: 27 start-page: 873 year: 1995 ident: 10.1016/j.jaci.2017.02.013_bib8 article-title: OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity publication-title: Transplant Proc – volume: 50 start-page: 355 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib115 article-title: Future biologic therapies in asthma publication-title: Arch Bronconeumol doi: 10.1016/j.arbres.2014.02.002 – volume: 74 start-page: 2006 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib42 article-title: Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial) publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-205067 – volume: 15 start-page: 3266 year: 1997 ident: 10.1016/j.jaci.2017.02.013_bib86 article-title: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.1997.15.10.3266 – volume: 355 start-page: 1018 year: 2006 ident: 10.1016/j.jaci.2017.02.013_bib14 article-title: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 publication-title: N Engl J Med doi: 10.1056/NEJMoa063842 – start-page: 193 year: 2007 ident: 10.1016/j.jaci.2017.02.013_bib6 – volume: 41 start-page: 256 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib57 article-title: Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2010.11.002 – volume: 65 start-page: 243 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib114 article-title: Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine publication-title: Allergol Int doi: 10.1016/j.alit.2016.04.011 – volume: 360 start-page: 2416 year: 2009 ident: 10.1016/j.jaci.2017.02.013_bib76 article-title: Use of canakinumab in the cryopyrin-associated periodic syndrome publication-title: N Engl J Med doi: 10.1056/NEJMoa0810787 – volume: 2 start-page: 594 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib38 article-title: Rituximab and immune deficiency: case series and review of the literature publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2014.06.003 – volume: 162 start-page: 62 year: 2013 ident: 10.1016/j.jaci.2017.02.013_bib45 article-title: Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria publication-title: Br J Haematol doi: 10.1111/bjh.12347 – volume: 10 start-page: 535 year: 2010 ident: 10.1016/j.jaci.2017.02.013_bib33 article-title: A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study) publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2009.03005.x – volume: 7 start-page: 122 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib41 article-title: B-cell survival factors in autoimmune rheumatic disorders publication-title: Ther Adv Musculoskelet Dis doi: 10.1177/1759720X15586782 – volume: 363 start-page: 711 year: 2010 ident: 10.1016/j.jaci.2017.02.013_bib17 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1003466 – volume: 37 start-page: 281 year: 2008 ident: 10.1016/j.jaci.2017.02.013_bib52 article-title: Tumor necrosis factor-alpha antagonists and neuropathy publication-title: Muscle Nerve doi: 10.1002/mus.20924 – volume: 386 start-page: 1137 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib98 article-title: Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)61134-5 – volume: 58 start-page: 1033 year: 2009 ident: 10.1016/j.jaci.2017.02.013_bib3 article-title: Dermatological complications and safety of anti-TNF treatments publication-title: Gut doi: 10.1136/gut.2008.163683 – volume: 61 start-page: 1693 year: 2012 ident: 10.1016/j.jaci.2017.02.013_bib48 article-title: Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial publication-title: Gut doi: 10.1136/gutjnl-2011-301668 – year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib84 – volume: 14 start-page: 96 year: 2007 ident: 10.1016/j.jaci.2017.02.013_bib36 article-title: Hematology Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Alemtuzumab in chronic lymphocytic leukemia publication-title: Curr Oncol doi: 10.3747/co.2007.118 – volume: 17 start-page: 6958 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib19 article-title: Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1595 – volume: 345 start-page: 1098 year: 2001 ident: 10.1016/j.jaci.2017.02.013_bib87 article-title: Tuberculosis associated with infliximab, a tumor necrosis factor α–neutralizing agent publication-title: N Engl J Med doi: 10.1056/NEJMoa011110 – volume: 16 start-page: 702 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib111 article-title: PI3Kδ and primary immunodeficiencies publication-title: Nat Rev Immunol doi: 10.1038/nri.2016.93 – volume: 353 start-page: 414 year: 2005 ident: 10.1016/j.jaci.2017.02.013_bib63 article-title: Progressive Multifocal leukoencephalopathy and natalizumab—unforeseen consequences publication-title: N Engl J Med doi: 10.1056/NEJMe058122 – volume: 374 start-page: 333 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib32 article-title: Belatacept and long-term outcomes in kidney transplantation publication-title: N Engl J Med doi: 10.1056/NEJMoa1506027 – volume: 218 start-page: 1304 year: 2013 ident: 10.1016/j.jaci.2017.02.013_bib94 article-title: Primary complement C5 deficiencies—Molecular characterization and clinical review of two families publication-title: Immunobiology doi: 10.1016/j.imbio.2013.04.021 – volume: 124 start-page: 386 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib101 article-title: BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases publication-title: Am J Med doi: 10.1016/j.amjmed.2010.11.028 – volume: 79 start-page: 457 year: 2012 ident: 10.1016/j.jaci.2017.02.013_bib4 article-title: Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series publication-title: Joint Bone Spine doi: 10.1016/j.jbspin.2011.10.001 – volume: 54 start-page: 2807 year: 2006 ident: 10.1016/j.jaci.2017.02.013_bib72 article-title: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study publication-title: Arthritis Rheum doi: 10.1002/art.22070 – volume: 5 start-page: 499 year: 2009 ident: 10.1016/j.jaci.2017.02.013_bib11 article-title: Monoclonal antibody-induced cytokine-release syndrome publication-title: Expert Rev Clin Immunol doi: 10.1586/eci.09.31 – volume: 9 start-page: 419 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib23 article-title: Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer publication-title: Expert Rev Clin Pharmacol doi: 10.1586/17512433.2016.1133289 – volume: 358 start-page: 2735 year: 2008 ident: 10.1016/j.jaci.2017.02.013_bib104 article-title: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose publication-title: N Engl J Med doi: 10.1056/NEJMc080834 – year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib21 article-title: Cancer immunotherapy in patients with preexisting autoimmune disorders publication-title: Semin Immunopathol – volume: 371 start-page: 1665 year: 2008 ident: 10.1016/j.jaci.2017.02.013_bib78 article-title: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) publication-title: Lancet doi: 10.1016/S0140-6736(08)60725-4 – volume: 57 start-page: 849 year: 2013 ident: 10.1016/j.jaci.2017.02.013_bib64 article-title: Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients publication-title: Clin Infect Dis doi: 10.1093/cid/cit376 – volume: 152 start-page: 486 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib47 article-title: Perianal dermatophytosis during secukinumab therapy for plaque psoriasis publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2015.4992 – volume: 223 start-page: 311 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib60 article-title: Eosinophilia during psoriasis treatment with TNF antagonists publication-title: Dermatology doi: 10.1159/000334805 – volume: 2014 start-page: 1 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib121 article-title: Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine publication-title: Mediators Inflamm doi: 10.1155/2014/386148 – volume: 94 start-page: 2217 year: 1999 ident: 10.1016/j.jaci.2017.02.013_bib9 article-title: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) publication-title: Blood doi: 10.1182/blood.V94.7.2217.419k02_2217_2224 – volume: 9 start-page: 188 year: 2010 ident: 10.1016/j.jaci.2017.02.013_bib55 article-title: Autoimmune diseases induced by biological agents: a double-edged sword? publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2009.10.003 – volume: 314 start-page: 308 year: 2006 ident: 10.1016/j.jaci.2017.02.013_bib73 article-title: Herpes simplex virus encephalitis in human UNC-93B deficiency publication-title: Science doi: 10.1126/science.1128346 – volume: 136 start-page: 1407 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib40 article-title: Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long? publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2015.06.035 – start-page: 111 year: 2007 ident: 10.1016/j.jaci.2017.02.013_bib13 – volume: 40 start-page: 147 year: 2010 ident: 10.1016/j.jaci.2017.02.013_bib53 article-title: Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2009.09.001 – volume: 56 start-page: 958 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib54 article-title: Drug-induced autoimmune-like hepatitis publication-title: Dig Dis Sci doi: 10.1007/s10620-011-1611-4 – volume: 15 start-page: 486 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib15 article-title: Molecular and cellular insights into T cell exhaustion publication-title: Nat Rev Immunol doi: 10.1038/nri3862 – volume: 138 start-page: 1531 year: 2016 ident: 10.1016/j.jaci.2017.02.013_bib2 article-title: Advances in clinical immunology in 2015 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2016.10.005 – volume: 31 start-page: 557 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib100 article-title: Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk publication-title: Curr Med Res Opin doi: 10.1185/03007995.2015.1011778 – volume: 371 start-page: 1198 year: 2014 ident: 10.1016/j.jaci.2017.02.013_bib118 article-title: Mepolizumab treatment in patients with severe eosinophilic asthma publication-title: N Engl J Med doi: 10.1056/NEJMoa1403290 – volume: 39 start-page: 242 year: 2012 ident: 10.1016/j.jaci.2017.02.013_bib29 article-title: Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial publication-title: J Dermatol doi: 10.1111/j.1346-8138.2011.01347.x – volume: 31 start-page: 410 year: 2012 ident: 10.1016/j.jaci.2017.02.013_bib109 article-title: Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease publication-title: Int Rev Immunol doi: 10.3109/08830185.2012.690794 – volume: 90 start-page: 2541 year: 1997 ident: 10.1016/j.jaci.2017.02.013_bib70 article-title: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production publication-title: Blood – volume: 70 start-page: 2003 year: 2011 ident: 10.1016/j.jaci.2017.02.013_bib61 article-title: Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2011-200316 – volume: 16 start-page: 2825 year: 1998 ident: 10.1016/j.jaci.2017.02.013_bib85 article-title: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.8.2825 – volume: 3 start-page: 355 year: 2015 ident: 10.1016/j.jaci.2017.02.013_bib120 article-title: Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(15)00042-9 |
| SSID | ssj0009389 |
| Score | 2.3475552 |
| SecondaryResourceType | review_article |
| Snippet | The field of biologic immune modulators is currently mushrooming at a dizzying pace. Although most of these biologics are tested and approved for one or a few... Abstract The field of biologic immune-modulators is currently mushrooming at a dizzying pace. While most of these biologics are tested and approved for one or... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1445 |
| SubjectTerms | Allergy and Immunology Animals Apoptosis Arthritis Arthritis, Rheumatoid - drug therapy Asthma Asthma - drug therapy Autoimmune diseases autoimmunity biologic response modifiers Biological Products - adverse effects Biological Products - pharmacology Biological Products - therapeutic use Biologics Cytokines Cytokines - immunology Cytotoxicity Homeostasis Human subjects Humans immune dysfunction Immune response Immune system immunodeficiency Immunologic Factors - adverse effects Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Immunomodulation infection Inflammatory bowel disease Inflammatory Bowel Diseases - drug therapy Lymphocytes Mutation Rhinitis - drug therapy Side effects Sinusitis - drug therapy Skin Spondylitis, Ankylosing - drug therapy T cell receptors |
| Title | Biologic response modifiers: Indications, implications, and insights |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0091674917303354 https://www.clinicalkey.es/playcontent/1-s2.0-S0091674917303354 https://dx.doi.org/10.1016/j.jaci.2017.02.013 https://www.ncbi.nlm.nih.gov/pubmed/28263774 https://www.proquest.com/docview/1895500885 |
| Volume | 139 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8RADA6iIF7Et-tj6cGbVredTnfqbfHBquhJwdvQeUFFq9j16m832Zmuii_w2DLptCH9krRfEoAdkWNcnBYizrMSExRbiljonorROzktlFYuo0Lhy6t8eJOd3_LbKThqa2GIVhmw32P6GK3DmYOgzYOnqqIa34Io9JhvIAwzTj1Bs6xPVr7_-k7zKJjwIXCRxLQ6FM54jtddqSuid_XHfTsT9pNz-in4HDuh0wWYD9FjNPA3uAhTtl6C2cvwf3wZjv1oyUpHz577aqOHR1M5mnd9GJ3Vpv1CtxdVH6jke1FZm6iqG8rUmxW4OT25PhrGYU5CrDnLRrGi37qusFmqTUle1-RM29QqrnKljeAOEc1ZzYTBcCspy7zHMswkNLfM5FqxVZiuH2u7DlFhlWOmtH26Mg2D4Y5TSqFTxEHnXAeSVkFShybiNMviXrZssTtJSpWkVNlLJSq1A7sTmSffQuPX1azVu2yLQxHOJCL8r1L976RsE97IRiaywZXyi9V0gE8kPxnenztutUYh3zcRBWZ8CNy8A2veUCaPjLltzjDY3vjnhpswR0eebLkF06PnF7uNAdFIdccW34WZwdnF8OoNvCgIkg |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-NADLbYIu1yQbDPLq8c9rZENJlMOuGGeKgF2lMr9TbKvKSg3YBI-f9rdyYFBHQlrkmcSSzns535bAP8EjnGxWkh4jwrMUGxpYiF7qkYvZPTQmnlMioUHo3zwTS7nPHZGpy2tTBEqwzY7zF9gdbhyFHQ5tFdVVGNb0EUesw3EIYZzz7AOnWn4h1YPxleDcaPvXeZ8FFwkcQkEGpnPM3rptQVMbz6i9adCXvLP70Vfy780MUWbIYAMjrxz7gNa7b-DB9HYYv8C5z56ZKVju49_dVGf29N5Wjk9XE0rE37k-4wqp6wyQ-jsjZRVTeUrDdfYXpxPjkdxGFUQqw5y-axop1dV9gs1aYkx2typm1qFVe50kZwh6DmrGbCYMSVlGXeYxkmE5pbZnKt2Dfo1Le1_QFRYZVjprR9ujPNg-GOU1ahU4RC51wXklZBUoc-4jTO4o9sCWM3kpQqSamyl0pUahd-L2XufBeNlVezVu-yrQ9FRJMI8iul-q9J2SZ8lI1MZINXyheG0wW-lHxme_9dcbc1Cvm4iCgw6UPs5l347g1l-cqY3uYM4-2f71zwAD4NJqNreT0cX-3ABp3x3Mtd6MzvH-wexkdztR_s_x_IMgtD |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biologic+response+modifiers%3A+Indications%2C+implications%2C+and+insights&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=Davis%2C+Benjamin+P.&rft.au=Ballas%2C+Zuhair+K.&rft.date=2017-05-01&rft.issn=0091-6749&rft.volume=139&rft.issue=5&rft.spage=1445&rft.epage=1456&rft_id=info:doi/10.1016%2Fj.jaci.2017.02.013&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jaci_2017_02_013 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-6749&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-6749&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-6749&client=summon |